BACE Inhibitor Improves Function in Mouse Models of Alzheimer’s Disease

BACE Inhibitor Improves Function in Mouse Models of Alzheimer’s Disease
A recent study in mice showed that BACE inhibitors not only reduce cerebral amyloid-beta (Aβ) levels, but they also may improve the neural circuit and memory impairments in patients with Alzheimer’s disease. Researchers now plan to conduct a large-scale clinical trial with about 1,000 patients to determine in the unexpected and encouraging results found in mouse

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. On new Base Inhibitor study, please send me information, news, and clinical trial information. Also send news the 1000 people that are applying for this clinical trial. I was in the Merc MK 8931 mild to moderate base inhibitor trisl phase 3 and they discontinued it telling us it was ineffective.
    If there’s new basevinhititir trial that’s promising, I want to be included.

  2. Eliseo Martinez says:

    Before clinical trials how about verifying with a duplicate study? Or concurrently. So much effort on amyloid is taking away talent that should be looking upstream at the genome, factors such as the role of histone misfolding and kyneuronins.

Leave a Comment

Your email address will not be published. Required fields are marked *